The popularity of Sildenafil initially sparked a period of growth for major pharmaceutical companies, but recent changes present a murky outlook for shareholders. Off-patent competitors are eating into earnings, and https://mathexqdv821672.digitollblog.com/41113363/sildenafil-and-the-pharmaceutical-industry-a-precarious-play